Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 148
Filtrar
1.
J Am Soc Nephrol ; 33(2): 259-278, 2022 02.
Artigo em Inglês | MEDLINE | ID: mdl-34907031

RESUMO

Kidney disease is a known risk factor for poor outcomes of COVID-19 and many other serious infections. Conversely, infection is the second most common cause of death in patients with kidney disease. However, little is known about the underlying secondary immunodeficiency related to kidney disease (SIDKD). In contrast to cardiovascular disease related to kidney disease, which has triggered countless epidemiologic, clinical, and experimental research activities or interventional trials, investments in tracing, understanding, and therapeutically targeting SIDKD have been sparse. As a call for more awareness of SIDKD as an imminent unmet medical need that requires rigorous research activities at all levels, we review the epidemiology of SIDKD and the numerous aspects of the abnormal immunophenotype of patients with kidney disease. We propose a definition of SIDKD and discuss the pathogenic mechanisms of SIDKD known thus far, including more recent insights into the unexpected immunoregulatory roles of elevated levels of FGF23 and hyperuricemia and shifts in the secretome of the intestinal microbiota in kidney disease. As an ultimate goal, we should aim to develop therapeutics that can reduce mortality due to infections in patients with kidney disease by normalizing host defense to pathogens and immune responses to vaccines.


Assuntos
COVID-19/etiologia , Síndromes de Imunodeficiência/etiologia , Insuficiência Renal Crônica/complicações , Imunidade Adaptativa , Plaquetas/imunologia , COVID-19/imunologia , Vacinas contra COVID-19/imunologia , Microbioma Gastrointestinal/imunologia , Humanos , Imunidade Inata , Síndromes de Imunodeficiência/imunologia , Síndromes de Imunodeficiência/prevenção & controle , Imunofenotipagem , Modelos Imunológicos , Pandemias , Insuficiência Renal Crônica/imunologia , Fatores de Risco , SARS-CoV-2 , Soroconversão
2.
Oxid Med Cell Longev ; 2021: 7571132, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34349875

RESUMO

The Glycyrrhiza genus, generally well-known as licorice, is broadly used for food and medicinal purposes around the globe. The genus encompasses a rich pool of bioactive molecules including triterpene saponins (e.g., glycyrrhizin) and flavonoids (e.g., liquiritigenin, liquiritin). This genus is being increasingly exploited for its biological effects such as antioxidant, antibacterial, antifungal, anti-inflammatory, antiproliferative, and cytotoxic activities. The species Glycyrrhiza glabra L. and the compound glycyrrhizin (glycyrrhizic acid) have been studied immensely for their effect on humans. The efficacy of the compound has been reported to be significantly higher on viral hepatitis and immune deficiency syndrome. This review provides up-to-date data on the most widely investigated Glycyrrhiza species for food and medicinal purposes, with special emphasis on secondary metabolites' composition and bioactive effects.


Assuntos
Anti-Inflamatórios/farmacocinética , Antioxidantes/farmacologia , Glycyrrhiza/química , Ácido Glicirrízico/farmacologia , Síndromes de Imunodeficiência/prevenção & controle , Inflamação/prevenção & controle , Compostos Fitoquímicos/farmacologia , Animais , Humanos , Síndromes de Imunodeficiência/patologia , Inflamação/patologia
3.
Hum Genet ; 139(6-7): 707-721, 2020 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-32232558

RESUMO

The transcription factor IRF8 (ICSBP) is required for the development and maturation of myeloid cells (dendritic cells, monocytes, macrophages), and for expression of intrinsic anti-microbial function such as antigen capture, processing and presentation to lymphoid cells, and for activation of these cells in response to cytokines and pro-inflammatory stimuli (IFN-γ, IFN-ß, LPS). IRF8 deficiency in humans causes a severe primary immunodeficiency presenting as susceptibility to infections, complete or severe depletion of blood dendritic cells (DC) subsets, depletion of CD14+ and CD16+ monocytes and reduced numbers and impaired activity of NK cells. In genome-wide association studies (GWAS), sequence variants near IRF8 are significant risk factors for multiple chronic inflammatory diseases in humans including inflammatory bowel disease, lupus, rheumatoid arthritis, multiple sclerosis, and several others. Recent studies have cataloged all the genes bound by and transcriptionally activated by IRF8 in myeloid cells, either alone or in combination with other transcription factors (PU.1, IRF1, STAT1) at steady state and in response to pro-inflammatory stimuli. This IRF1/IRF8 regulome comprises immune pathways such as antigen processing and presentation pathways, expression of costimulatory molecules, cytokines and chemokines, response to stimuli such as cytokine receptors, pathogen-associated molecular pattern receptors, TLRs and nucleotide-binding oligomerization domain-like receptor signaling pathways, and small antiviral GTPases. Members of the IRF8/IRF1 regulome are over-represented amongst genes in which mutations cause primary immunodeficiencies, and are specifically enriched at GWAS loci associated with chronic inflammatory diseases in humans. These recent studies highlight a critical role of IRF8 in the activity of several immune cell types for protection against infections, but also in pathological inflammation associated with common human inflammatory conditions.


Assuntos
Síndromes de Imunodeficiência/etiologia , Síndromes de Imunodeficiência/prevenção & controle , Inflamação/etiologia , Inflamação/prevenção & controle , Fatores Reguladores de Interferon/metabolismo , Linfócitos/imunologia , Células Mieloides/imunologia , Animais , Humanos , Síndromes de Imunodeficiência/metabolismo , Inflamação/metabolismo , Fatores Reguladores de Interferon/genética , Linfócitos/metabolismo , Mutação , Células Mieloides/metabolismo
4.
Front Biosci (Landmark Ed) ; 23(5): 909-920, 2018 01 01.
Artigo em Inglês | MEDLINE | ID: mdl-28930580

RESUMO

We review the progression of aging as a sequential development of multiple syndromes analogous to other diseases. This generalized approach may allow practicing physicians to consider the signs of aging as manifestations of a poly-syndrome disease and facilitate prevention, diagnosis and treatment of common aging-related dysfunctions.


Assuntos
Envelhecimento/efeitos dos fármacos , Síndromes de Imunodeficiência/prevenção & controle , Osteoporose/prevenção & controle , Estresse Oxidativo/efeitos dos fármacos , Substâncias Protetoras/administração & dosagem , Envelhecimento/imunologia , Envelhecimento/patologia , Geriatria/métodos , Humanos , Síndromes de Imunodeficiência/imunologia , Longevidade/efeitos dos fármacos , Modelos Biológicos , Osteoporose/fisiopatologia , Síndrome
5.
Pediatr Infect Dis J ; 36(5): 457-461, 2017 05.
Artigo em Inglês | MEDLINE | ID: mdl-28403047

RESUMO

BACKGROUND: The occurrence of meningitis in children >5 years old may be associated with specific predisposing factors that can be anatomic, such as cerebrospinal fluid fistula or breach, or related to genetic susceptibility or N inborn or acquired immunologic defect. This study aimed to assess the anatomical and immunologic risk factors in children >5 years old with pneumococcal meningitis and prospectively enrolled in the French national meningitis network. METHODS: We analyzed all data for children who were 5-15 years old with a diagnosis of pneumococcal meningitis between 2001 and 2013. We describe the frequency and typology of the anatomic or immunologic risk factors, the clinical features and the pneumococcal serotypes. RESULTS: Among the 316 patients with pneumococcal meningitis, the mortality rate was 9.5% and 23.1% of cases presented complications (abscess, coma, hemodynamic failure, thrombophlebitis cerebral or deafness). In total, 108 children (34%) showed risk factors, the most frequent being anatomic: 70 cases (22.8%) were related to a cerebrospinal fluid breach or fistula and 55 (17.9%) to immunodeficiency, primary or acquired. Serotype data were available for 207 pneumococcal isolates (65.5%). The most frequent serotypes were as follows: 3, 18C, 19A and 19F between 2001 and 2009 and 19F, 3, 19A, 12F, 22F, 17F and 24F after 2009. CONCLUSIONS: We describe the largest cohort of children >5 years old with pneumococcal meningitis. One third of the children had risk factors justifying a complete immunologic and radiologic work-up.


Assuntos
Síndromes de Imunodeficiência/diagnóstico , Síndromes de Imunodeficiência/prevenção & controle , Meningite Pneumocócica/diagnóstico , Vacinas Pneumocócicas/administração & dosagem , Streptococcus pneumoniae/patogenicidade , Vacinação , Abscesso/diagnóstico , Abscesso/etiologia , Abscesso/mortalidade , Abscesso/prevenção & controle , Adolescente , Criança , Pré-Escolar , Coma/diagnóstico , Coma/etiologia , Coma/mortalidade , Coma/prevenção & controle , Surdez/diagnóstico , Surdez/etiologia , Surdez/mortalidade , Surdez/prevenção & controle , Feminino , França , Humanos , Síndromes de Imunodeficiência/complicações , Síndromes de Imunodeficiência/mortalidade , Masculino , Meningite Pneumocócica/complicações , Meningite Pneumocócica/mortalidade , Meningite Pneumocócica/prevenção & controle , Estudos Prospectivos , Fatores de Risco , Sorogrupo , Streptococcus pneumoniae/classificação , Streptococcus pneumoniae/isolamento & purificação , Análise de Sobrevida , Tromboflebite/diagnóstico , Tromboflebite/etiologia , Tromboflebite/mortalidade , Tromboflebite/prevenção & controle
6.
Pharm Biol ; 55(1): 1358-1367, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-28303736

RESUMO

CONTEXT: Chronic stress is an inevitable factor in the modern day society which affects cell mediated as well as humoral immunity. There is a need to prevent stress effects with traditionally used herbs. OBJECTIVE: The present study was undertaken to investigate the immunoprotective effect of Vacha (Acorus calamus L. Acoraceae) rhizome under stressful condition. MATERIALS AND METHODS: Soxlet extraction of Vacha rhizome was performed with increasing polarity of solvents, i.e., petroleum ether to ethanol. The extract was concentrated by distilling off the solvent in flash evaporator and dried in desiccators. The benzene extract was found to have anti-stress property in our earlier studies and hence it was used in the present experiment. Extract was administered every day for 4 weeks orally to adult female rats prior to exposure to stress, restraint (1 h) and forced swimming exercise (15 min). RESULTS: Vacha rhizome extract significantly prevented the stress induced reduction in total and differential leukocytes count, immunoglobulin content, bone marrow cellularity and viability, lymphocytes counts in lymphoid organs, islands of white pulp of spleen (ED50 = 10 mg, p < 0.001) and a significant increase in circulating immune complexes and apoptotic index of lymphoid organs (ED50 = 10 mg, p < 0.001) compared to controls. DISCUSSION AND CONCLUSION: The present study clearly indicates that Vacha extract not only prevents stress-induced suppression of immunity and structural involution of lymphoid organs, but also boosts immunity in normal rats. Therefore, it is suggested that Vacha extract administration maintains normal immunity despite the body experiencing stress.


Assuntos
Acorus , Síndromes de Imunodeficiência/prevenção & controle , Fitoterapia , Extratos Vegetais/uso terapêutico , Estresse Psicológico/imunologia , Animais , Apoptose/efeitos dos fármacos , Peso Corporal , Feminino , Células-Tronco Hematopoéticas/efeitos dos fármacos , Tamanho do Órgão , Substâncias Protetoras/farmacologia , Ratos , Ratos Wistar , Rizoma
7.
Hematol Oncol ; 34(3): 121-32, 2016 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-27402426

RESUMO

Secondary immunodeficiencies occur as a consequence of various diseases, including hematological malignancies, and the use of pharmacological therapies, such as immunosuppressive, anti-inflammatory, and biological drugs. Infections are the main cause of morbidity and mortality in multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) patients. Recent advances in treatment have prolonged the duration of remission and the time between relapse phases in MM and CLL patients. However, managing multiple relapses and the use of salvage therapies can lead to cumulative immunosuppression and a higher risk of infections. The pathogenesis of immune deficiency secondary to lymphoproliferative malignancy is multifactorial including disease- and treatment-related factors. Supportive treatment, including early vaccination, anti-infective prophylaxis, and replacement immunoglobulin, plays a key role in preventing infections in MM and CLL. This article provides an overview of the basic immunology necessary to understand the pathogenesis of secondary immunodeficiency and the infectious complications in MM and CLL. We also discuss the evidence supporting the role of prophylactic replacement immunoglobulin treatment in patients with antibody failure secondary to MM and CLL and the indications for its use. Copyright © 2016 John Wiley & Sons, Ltd.


Assuntos
Neoplasias Hematológicas/terapia , Síndromes de Imunodeficiência/etiologia , Síndromes de Imunodeficiência/imunologia , Síndromes de Imunodeficiência/prevenção & controle , Leucemia Linfocítica Crônica de Células B/terapia , Mieloma Múltiplo/terapia , Feminino , Neoplasias Hematológicas/imunologia , Humanos , Leucemia Linfocítica Crônica de Células B/imunologia , Masculino , Mieloma Múltiplo/imunologia
8.
Expert Rev Clin Immunol ; 12(9): 921-6, 2016 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-27415820

RESUMO

INTRODUCTION: In primary immunodeficiency (PID), immunoglobulin replacement therapy (IgRT) for infection prevention is well-established and supported by a wealth of clinical data. On the contrary, very little evidence-based data is available on the challenges surrounding the use of IgRT in secondary immune deficiencies (SID), and most published guidelines are mere extrapolations from the experience in PID. AREAS COVERED: In this article, four European experts provide their consolidated opinion on open questions surrounding the prophylactic use of IgRT in SID, based on their clinical experience. The main topics are IgRT initiation, route of administration, dose optimization, and therapy discontinuation. The authors hope this discussion will be of assistance to practicing physicians in their daily decision-making. Expert commentary: Although growing experience indicates that IgRT could play an important role in the management of SID, very little robust evidence is available to guide clinical practice. The authors stress the urgent need for new studies in the field and discuss points they find of importance to design them adequately.


Assuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/tratamento farmacológico , Neoplasias Hematológicas/tratamento farmacológico , Imunoglobulinas Intravenosas/uso terapêutico , Síndromes de Imunodeficiência/prevenção & controle , Animais , Protocolos Clínicos , Europa (Continente) , Medicina Baseada em Evidências , Prova Pericial , Neoplasias Hematológicas/complicações , Humanos , Síndromes de Imunodeficiência/etiologia
9.
Hum Vaccin Immunother ; 12(2): 285-92, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-26905679

RESUMO

Routine infant immunization with 10-valent pneumococcal conjugate vaccine (PCV-10) began in Brazil in 2010. The impact of the PCV-10 on rates of invasive pneumococcal disease (IPD) at the population level was not yet evaluated. Serotype-specific IPD changes after PCV-10 introduction is still to be determined. Data from national surveillance system for notifiable diseases (SINAN) and national reference laboratory for S. pneumoniae in Brazil (IAL) were linked to enhance case ascertainment of IPD. An interrupted time-series analysis was conducted to predict trends in the postvaccination IPD rates in the absence of PCV-10 vaccination, taking into consideration seasonality and secular trends. PCVs serotype-specific distribution were assessed before (2008-2009) and after (2011-2013) the introduction of PCV-10 in the immunization program. A total of 9,827 IPD cases were identified from 2008-2013 when combining SINAN and IAL databases. Overall, PCV-10 types decreased by 41.3% after PCV-10 vaccination period, mostly in children aged 2-23 months, while additional PCV-13 serotypes increased by 62.8% mainly in children under 5-year of age. For children aged 2-23 months, targeted by the immunization program, we observed a 44.2% (95%CI, 15.8-72.5%) reduction in IPD rates. In contrast, significant increase in IPD rates were observed for adults aged 18-39 y (18.9%, 95%CI 1.1-36.7%), 40-64 y (52.5%, 95%CI 24.8-80.3%), and elderly ≥ 65 y (79.3%, 95%CI 62.1-96.5%). This is the first report of a time-series analysis for PCV impact in IPD conducted at national level data in a developing country. We were able to show significant impact of PCV-10 on IPD for age groups targeted by vaccination in Brazil, 3 y after its introduction. No impact on other age groups was demonstrated.


Assuntos
Programas de Imunização , Síndromes de Imunodeficiência/epidemiologia , Meningite Pneumocócica/epidemiologia , Infecções Pneumocócicas/epidemiologia , Vacinas Pneumocócicas/imunologia , Vacinas Conjugadas/imunologia , Adolescente , Adulto , Brasil/epidemiologia , Criança , Pré-Escolar , Humanos , Síndromes de Imunodeficiência/microbiologia , Síndromes de Imunodeficiência/prevenção & controle , Lactente , Quinases Associadas a Receptores de Interleucina-1 , Meningite Pneumocócica/microbiologia , Meningite Pneumocócica/prevenção & controle , Pessoa de Meia-Idade , Infecções Pneumocócicas/microbiologia , Infecções Pneumocócicas/prevenção & controle , Doenças da Imunodeficiência Primária , Sorogrupo , Streptococcus pneumoniae/imunologia , Vacinação , Adulto Jovem
10.
Toxicol Ind Health ; 32(9): 1564-9, 2016 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-25653037

RESUMO

AIM: This study was carried out to determine the effects of formaldehyde (FA) inhalation on the humoral immunity of rats and the protective effect of Nigella sativa (NS) oil. MATERIALS AND METHODS: The rats (n = 33) were divided into five groups, with five animals in the control group (FA-free air) and seven in the other four groups. Group FA1 was exposed to FA (5 ppm), group FA + NS1 was treated with NS and exposed to FA (5 ppm), group FA2 was exposed to FA (10 ppm), and group FA + NS2 was treated with NS and exposed to FA (10 ppm). At the end of a 4-week study period, blood samples were collected. Enzyme-linked immunosorbent assay was used to determine the levels of serum total immunoglobulin A (IgA), total immunoglobulin M (IgM), total immunoglobulin G (IgG), and complement 3 (C3). RESULTS: FA inhalation significantly increased serum IgA, IgM, and C3 levels and decreased serum IgG levels compared with the control group. NS administration decreased serum IgA, IgM, and C3 levels, which were induced by FA inhalation. CONCLUSION: FA inhalation significantly increased acute antibody responses and C3 levels in a dose-dependent manner compared with the control group. FA inhalation decreased the secondary immune response compared with the control group. Levels of acute antibody responses and complement following exposure to FA inhalation returned to normal following treatment with NS (immunoregulatory effect). However, NS did not affect the secondary immune response.


Assuntos
Carcinógenos Ambientais/toxicidade , Suplementos Nutricionais , Formaldeído/toxicidade , Imunidade Humoral/efeitos dos fármacos , Síndromes de Imunodeficiência/prevenção & controle , Óleos de Plantas/uso terapêutico , Substâncias Protetoras/uso terapêutico , Administração por Inalação , Poluentes Atmosféricos/química , Poluentes Atmosféricos/toxicidade , Animais , Formação de Anticorpos/efeitos dos fármacos , Anticarcinógenos/uso terapêutico , Câmaras de Exposição Atmosférica , Carcinógenos Ambientais/administração & dosagem , Carcinógenos Ambientais/química , Complemento C3/agonistas , Complemento C3/análise , Complemento C3/antagonistas & inibidores , Relação Dose-Resposta a Droga , Formaldeído/administração & dosagem , Formaldeído/antagonistas & inibidores , Imunoglobulina A/análise , Imunoglobulina A/biossíntese , Imunoglobulina A/química , Imunoglobulina M/análise , Imunoglobulina M/biossíntese , Imunoglobulina M/química , Síndromes de Imunodeficiência/sangue , Síndromes de Imunodeficiência/induzido quimicamente , Síndromes de Imunodeficiência/imunologia , Exposição por Inalação/efeitos adversos , Masculino , Ratos Sprague-Dawley
11.
Clin Nutr ESPEN ; 11: e1-e11, 2016 02.
Artigo em Inglês | MEDLINE | ID: mdl-28531420

RESUMO

Anemia in elderly population have a great incidence and is related to increased mortality risk. The incidence of nutrition in anemia is about one third of the total. Caloric and protein restriction, iron, vitamin B12, folic deficiency are the causes of nutritional anemia. Protein and energy malnutrition stimulate an increased cytokines production with induction of inflammation, immunodeficiency and anemia. Anorexia and obesity can be associated with anemia due to increased cytokines and hepdicin serum level. Macrophages activity is inhibited and a decrease in red blood cells (RBC), hemoglobin (Hb) concentration due to ineffective erythropoiesis is observed. An adequate energy and protein diet is necessary to reduce inflammation and increase iron absorption. A minimum of 1700 kcal/day and 1.7 gr/kg/day of protein intake are necessary to maintain anabolism in chronic patients to prevent and treat anemia. Iron supplementation by intravenous injection is safe and effective to correct severe iron deficiency. The supplementation of vitamins and oligomineral are useful to reduce oxidative stress and improve RBC longevity. Anemia in elderly could be prevented by an adequate nutrition, a simple and not expensive intervention, and associated to physical exercise reduce the incidence of mortality rate.


Assuntos
Anemia/prevenção & controle , Dieta Saudável , Suplementos Nutricionais , Fenômenos Fisiológicos da Nutrição do Idoso , Envelhecimento Saudável , Estilo de Vida Saudável , Cooperação do Paciente , Idoso , Idoso de 80 Anos ou mais , Anemia/epidemiologia , Anemia/etiologia , Anemia/imunologia , Anemia Ferropriva/epidemiologia , Anemia Ferropriva/etiologia , Anemia Ferropriva/imunologia , Anemia Ferropriva/prevenção & controle , Animais , Anorexia/epidemiologia , Anorexia/mortalidade , Anorexia/fisiopatologia , Anorexia/terapia , Terapia Combinada , Instituição de Longa Permanência para Idosos , Humanos , Síndromes de Imunodeficiência/epidemiologia , Síndromes de Imunodeficiência/etiologia , Síndromes de Imunodeficiência/imunologia , Síndromes de Imunodeficiência/prevenção & controle , Desnutrição/epidemiologia , Desnutrição/mortalidade , Desnutrição/fisiopatologia , Desnutrição/terapia , Casas de Saúde , Apoio Nutricional , Obesidade/epidemiologia , Obesidade/mortalidade , Obesidade/fisiopatologia , Obesidade/terapia
12.
Immunol Allergy Clin North Am ; 35(4): 599-623, 2015 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-26454309

RESUMO

The spectrum of primary immunodeficiency disorders (PIDs) is expanding. It includes typical disorders that primarily present with defective immunity as well as disorders that predominantly involve other systems and show few features of impaired immunity. The rapidly growing list of new immunodeficiency disorders and treatment modalities makes it imperative for providers to stay abreast of the latest and best management strategies. This article presents a brief overview of recent clinical advances in PIDs.


Assuntos
Síndromes de Imunodeficiência/diagnóstico , Síndromes de Imunodeficiência/terapia , Animais , Autoimunidade , Humanos , Imunidade , Síndromes de Imunodeficiência/epidemiologia , Síndromes de Imunodeficiência/etiologia , Síndromes de Imunodeficiência/prevenção & controle , Prognóstico , Transdução de Sinais
13.
Curr Opin Allergy Clin Immunol ; 15(6): 505-13, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26406183

RESUMO

PURPOSE OF REVIEW: Antibody deficiency can occur in the context of primary immune deficiency due to inherited genetic defects or secondary to a variety of causes. This review aims to summarize current data concerning the causes of secondary antibody deficiency and where possible evidence regarding the use of prophylactic replacement immunoglobulin. (Figure is included in full-text article.) RECENT FINDINGS: Advances in immune-mediated therapies ranging from monoclonal antibodies to novel B-cell-targeted therapeutics are responsible for an expansion in the possible iatrogenic causes of antibody deficiency. SUMMARY: Causes of secondary antibody deficiency include B-cell lymphoproliferative disease, notably chronic lymphocytic leukaemia and multiple myeloma, protein losing states, disorders of lymphatic circulation, increased immunoglobulin catabolism and a growing number of therapeutic agents. At-risk patients should be closely monitored for the development of hypogammaglobulinaemia, B-cell function should be defined where appropriate with specific antibody responses to immunization antigens and where there is a significant burden of infections patients should be treated with prophylactic antibiotics and/or replacement immunoglobulin.


Assuntos
Linfócitos B/imunologia , Doença Iatrogênica/prevenção & controle , Síndromes de Imunodeficiência/prevenção & controle , Infecções/imunologia , Leucemia Linfocítica Crônica de Células B/imunologia , Mieloma Múltiplo/imunologia , Animais , Antibioticoprofilaxia , Humanos , Imunoglobulinas Intravenosas/administração & dosagem , Síndromes de Imunodeficiência/etiologia , Infecções/complicações , Infecções/tratamento farmacológico , Leucemia Linfocítica Crônica de Células B/complicações , Leucemia Linfocítica Crônica de Células B/tratamento farmacológico , Mieloma Múltiplo/complicações , Mieloma Múltiplo/tratamento farmacológico
14.
PLoS One ; 10(3): e0120290, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25781031

RESUMO

BACKGROUND: The ten-valent pneumococcal conjugate vaccine (PCV10) was introduced into the Finnish National Vaccination Program (NVP) in September 2010 with a 2+1 schedule (3, 5, 12 months) without catch-up vaccinations. We evaluated the direct and indirect effects of PCV10 on invasive pneumococcal disease (IPD) among children ≤5 years of age during the first three years after NVP introduction. METHODS: We conducted a population-based, observational follow-up study. The cohort of vaccine-eligible children (all children born June 1, 2010 or later) was followed from 3 months of age until the end of 2013. For the indirect effect, another cohort of older children ineligible for PCV10 vaccination was followed from 2011 through 2013. Both cohorts were compared with season- and age-matched reference cohorts before NVP introduction. National, population-based laboratory surveillance data were used to compare culture-confirmed serotype-specific IPD rates in the vaccine target and reference cohorts by using Poisson regression models. RESULTS: The overall IPD rate among vaccine-eligible children was reduced by 80% (95%CI 72 to 85); the reduction in vaccine-type IPD was 92% (95%CI 86 to 95). However, a non-significant increase in non-vaccine type IPD was observed. During 2012-2013, we also observed a 48% (95%CI 18 to 69) reduction in IPD among unvaccinated children 2 to 5 years of age, which was mostly attributable to the ten vaccine serotypes. CONCLUSIONS: This is the first population-based study investigating the impact of PCV10 introduction without prior PCV7 use. A substantial decrease in IPD rates among vaccine-eligible children was observed. A smaller and temporally delayed reduction among older, unvaccinated children suggests that PCV10 also provides indirect protection against vaccine-type IPD. Changes in serotype distribution warrant continuous monitoring of potential increases in non-vaccine serotypes.


Assuntos
Síndromes de Imunodeficiência/prevenção & controle , Infecções Pneumocócicas/prevenção & controle , Vacinas Pneumocócicas/uso terapêutico , Vacinação/estatística & dados numéricos , Estudos de Casos e Controles , Criança , Pré-Escolar , Feminino , Finlândia , Humanos , Síndromes de Imunodeficiência/epidemiologia , Lactente , Masculino , Infecções Pneumocócicas/epidemiologia
15.
Z Rheumatol ; 72(7): 634-40, 642, 2013 Sep.
Artigo em Alemão | MEDLINE | ID: mdl-23942561

RESUMO

Immunosuppressive treatment plays a crucial role in the management of autoimmune and autoinflammatory diseases. Knowledge about the ensuing immune deficits resulting from these therapies as well as common infections in immunocompromised patients should be familiar to all doctors involved in the prescription and administration of immunosuppressive drugs. Comprehensive pretreatment screening, regular monitoring both during and following treatment as well common sense preventive measures, such as vaccination can help further minimise the risk of infection.


Assuntos
Síndromes de Imunodeficiência/induzido quimicamente , Síndromes de Imunodeficiência/prevenção & controle , Imunossupressores/efeitos adversos , Imunossupressores/uso terapêutico , Doenças Reumáticas/complicações , Doenças Reumáticas/tratamento farmacológico , Humanos
16.
Radiat Res ; 177(5): 676-84, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22439601

RESUMO

Whole body irradiated mice appear to experience a down-regulation of the helper T (Th)1-like immune response, and maintain a persistent immunological imbalance. In the current study, we evaluated the effect of HemoHIM (an herbal product made from Angelica Radix, Cnidium officinale , and Paeonia japonica cultivated in Korea) to ameliorate the immunological imbalance induce in fractionated γ-irradiated mice. The mice were exposed to γ rays twice a week (0.5 Gy fractions) for a total dose of 5 Gy, and HemoHIM was administrated orally from 1 week before the first irradiation to 1 week before the final analysis. All experiments were performed 4 and 6 months after their first exposure. HemoHIM ameliorated the Th1- and Th2-related immune responses normally occur in irradiated mice with or without dinitrophenylated keyhole limpet hemocyanin immunization. HemoHIM also restored the natural killer cell activities without changing the percentage of natural killer cells in irradiated mice. Furthermore, the administration of HemoHIM prevented the reduction in levels of interleukin-12p70 in irradiated mice. Finally, we found that HemoHIM enhanced the phosphorylation of signal transducer and activator of transcription (STAT) 4 that was reduced in irradiated mice. Our findings suggest that HemoHIM ameliorates the persistent down-regulation of Th1-like immune responses by modulating the IL-12p70/pSTAT4 signaling pathway.


Assuntos
Raios gama/efeitos adversos , Síndromes de Imunodeficiência/prevenção & controle , Interleucina-12/fisiologia , Células Matadoras Naturais/efeitos dos fármacos , Fitoterapia , Extratos Vegetais/uso terapêutico , Lesões Experimentais por Radiação/tratamento farmacológico , Protetores contra Radiação/uso terapêutico , Fator de Transcrição STAT4/fisiologia , Transdução de Sinais/efeitos dos fármacos , Células Th1/efeitos dos fármacos , Irradiação Corporal Total/efeitos adversos , Animais , Formação de Anticorpos/efeitos dos fármacos , Formação de Anticorpos/efeitos da radiação , Citotoxicidade Imunológica/efeitos dos fármacos , Citotoxicidade Imunológica/efeitos da radiação , Fracionamento da Dose de Radiação , Regulação para Baixo/efeitos dos fármacos , Avaliação Pré-Clínica de Medicamentos , Feminino , Imunização , Síndromes de Imunodeficiência/etiologia , Células Matadoras Naturais/imunologia , Células Matadoras Naturais/efeitos da radiação , Linfocinas/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Fosforilação/efeitos dos fármacos , Extratos Vegetais/farmacologia , Processamento de Proteína Pós-Traducional/efeitos dos fármacos , Lesões Experimentais por Radiação/imunologia , Protetores contra Radiação/farmacologia , Organismos Livres de Patógenos Específicos , Baço/imunologia , Baço/patologia , Baço/efeitos da radiação , Células Th1/metabolismo , Células Th1/efeitos da radiação , Células Th2/efeitos dos fármacos , Células Th2/metabolismo , Células Th2/efeitos da radiação
17.
Clin Dev Immunol ; 2012: 985646, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22235228

RESUMO

Placental transfer of maternal IgG antibodies to the fetus is an important mechanism that provides protection to the infant while his/her humoral response is inefficient. IgG is the only antibody class that significantly crosses the human placenta. This crossing is mediated by FcRn expressed on syncytiotrophoblast cells. There is evidence that IgG transfer depends on the following: (i) maternal levels of total IgG and specific antibodies, (ii) gestational age, (iii) placental integrity, (iv) IgG subclass, and (v) nature of antigen, being more intense for thymus-dependent ones. These features represent the basis for maternal immunization strategies aimed at protecting newborns against neonatal and infantile infectious diseases. In some situations, such as mothers with primary immunodeficiencies, exogenous IgG acquired by intravenous immunoglobulin therapy crosses the placenta in similar patterns to endogenous immunoglobulins and may also protect the offspring from infections in early life. Inversely, harmful autoantibodies may cross the placenta and cause transitory autoimmune disease in the neonate.


Assuntos
Imunidade Materno-Adquirida/imunologia , Imunoglobulina G/imunologia , Síndromes de Imunodeficiência/imunologia , Placenta/imunologia , Feminino , Humanos , Imunoglobulina G/metabolismo , Imunoglobulina G/uso terapêutico , Síndromes de Imunodeficiência/prevenção & controle , Recém-Nascido , Modelos Imunológicos , Placenta/metabolismo , Gravidez , Complicações na Gravidez
18.
Eksp Klin Farmakol ; 75(11): 31-4, 2012.
Artigo em Russo | MEDLINE | ID: mdl-23323331

RESUMO

The development of delayed disorders caused by acute ethylene glycol poisoning has been studied in experiments on male rats. These disorders include chronic renal failure and secondary combined immunodeficiency status of the "circulus vitiosus" type. Urgent pharmacological correction was shown to be necessary shortly after the poisoning. The experimental therapy (administration of immunomodulators with various mechanisms of action in addition to conventional antidote treatment with ethanol) resulted in the restoration of nonspecific resistance and both cellular and humoral immunity. Reduction of the urinary system damage after the administration of immunomodulators was observed. The results demonstrated the importance of multiagent immunotherapy for the correction of delayed effects of acute ethylene glycol poisoning.


Assuntos
Acridinas/farmacologia , Dipeptídeos/farmacologia , Síndromes de Imunodeficiência/prevenção & controle , Fatores Imunológicos/farmacologia , Falência Renal Crônica/prevenção & controle , Animais , Antídotos/farmacologia , Glicemia/análise , Creatinina/sangue , Citocinas/sangue , Etanol/farmacologia , Etilenoglicol , Imunidade Humoral/efeitos dos fármacos , Imunidade Inata/efeitos dos fármacos , Síndromes de Imunodeficiência/induzido quimicamente , Síndromes de Imunodeficiência/complicações , Falência Renal Crônica/induzido quimicamente , Falência Renal Crônica/complicações , Testes de Função Renal , Ácido Láctico/sangue , Masculino , Ratos , Ratos Wistar , Bicarbonato de Sódio/farmacologia
19.
Lik Sprava ; (6): 62-7, 2012.
Artigo em Russo | MEDLINE | ID: mdl-23373378

RESUMO

Factors, able to cause the second immunodeficit, are very various: sharp and chronic poisonings, protracted reception of some medicinal preparations, chronic stress and overstrain. The general line of the factors described higher is the complex negative affecting all systems of organism, including on the immune system. In addition, such factors as an ionizing radiation is also rendered electoral ingibiruyuschee operating on immunity, related to oppressing of the system of krovetvoreniya. Second immunodeficity carry coming character and treatment of second immunodeficitov much simpler and more effective as compared to treatment of primary parafunctions immune system. The restoration capabilities of the immune system are great, therefore the removal of reason of immunodeficit, as a rule, results in renewal of immune system.


Assuntos
Antibacterianos/uso terapêutico , Antivirais/uso terapêutico , Sistema Imunitário/efeitos dos fármacos , Infecções/tratamento farmacológico , Infecções/imunologia , Antibacterianos/administração & dosagem , Antivirais/administração & dosagem , Resistência a Medicamentos , Humanos , Síndromes de Imunodeficiência/prevenção & controle
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA